Following an encouraging year to date we have upgraded our forecasts for Xadago (Parkinson’s disease [PD] therapy), and key CNS pipeline assets sarizotan (Rett syndrome) and Evenamide (schizophrenia). Sublicensee partner US WorldMeds launched Xadago into the US market in July 2017; Xadago is now available in the majority of key markets worldwide through partners. Importantly Newron’s CNS R&D pipeline is progressing; clinical data and commercial opportunity details presented on Evenamide and sarizotan at the R&D day in May have prompted upgrades to our peak sales forecasts and valuation. Our updated valuation is CHF754m.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs